Martínez PS

Language: Spanish
References: 5
Page: 1-4
PDF size: 289.21 Kb.

Text Extraction

No abstract.

REFERENCES

1. Wang LS, Wang H, Zhang QL, Yang ZJ, Kong FX, Wu CT. Hepatocyte growth factor gene therapy for ischemic diseases. Hum Gene Ther. 2018;29(4):413-23. DOI: https://doi.org/10.1089/hum.2017.217

2. Barć P, Antkiewicz M, Śliwa B, Baczyńska D, Witkiewicz W, Skóra JP. Treatment of critical limb ischemia by pIRES/ VEGF165/ HGF administration. Ann Vasc Surg. 2019;60:346-54. DOI: https://doi.org/10.1016/j.avsg.2019.03.013

3. Gu Y, Cui S, Wang Q, Liu C, Jin B, Guo W, et al. A randomized, double-blind, placebo-controlled phase II study of hepatocyte growth factor in the treatment of critical limb ischemia. Mol Ther. 2019;27(12):2158-65. DOI: https://doi.org/10.1016/j.ymthe.2019.10.017

4. Kibbe MR, Hirsch AT, Mendelsohn FO, Davies MG, Pham H, Saucedo J, et al. Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Ther. 2016;23(3):306-12. DOI: https://doi.org/10.1038/gt.2015.110

5. Cui S, Guo L, Li X, Gu Y, Fu J, Dong L, et al. Clinical safety and preliminary efficacy of plasmid pUDK-HGF expressing human hepatocyte growth factor (HGF) in patients with critical limb ischemia. Eur J Vasc Endovasc Surg. 2015;50(4):494-501. DOI: https://doi.org/10.1016/j.ejvs.2015.05.007